NEW YORK (360Dx) – Biovica, a Swedish biotechnology company, aims to launch an assay for predicting and monitoring treatment response in cancer patients by 2020.
CEO Anders Rylander said the company will initially market its DiviTum assay for use in breast cancer, though it could be used to monitor cell proliferation in all cancer types. Biovica will seek regulatory clearance for its test in the US as well as in Europe, and is currently engaged in nearly a dozen studies aimed at assessing the test's performance in both regions, he said.